NY-ESO-1 and MAGE-A3 are not expressed by DCP-001 but were included to monitor for possible epitope spreading, i.e., T cell responses primed against epitopes released from the patients’ autologous blasts after a successful DCP-001 induced anti-AML immune response. This evidence concerns the gene MAGEA3 and acute myeloid leukemia.